Show simple item record

dc.contributor.authorSmyth, Elizabeth
dc.contributor.authorKnödler, Maren
dc.contributor.authorGiraut, Anne
dc.contributor.authorMauer, Murielle
dc.contributor.authorNilsson, Magnus
dc.contributor.authorVan Grieken, Nicole
dc.contributor.authorWagner, Anna Dorothea
dc.contributor.authorMoehler, Markus
dc.contributor.authorLordick, Florian
dc.date.accessioned2020-02-13T06:05:21Z
dc.date.available2020-02-13T06:05:21Z
dc.date.issued2020-01-30
dc.date.submitted2019-09-07
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/302092
dc.description.abstractBackground: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse following surgical resection. Patients who have a poor response to neoadjuvant chemotherapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence. Current clinical practice is to continue with the same chemotherapy in the adjuvant setting as before surgery. In the phase II randomized EORTC VESTIGE trial (NCT03443856), patients with high risk resected gastric or esophageal adenocarcinoma will be randomized to either adjuvant chemotherapy (as before surgery) or to immunotherapy with nivolumab and low dose ipilimumab (nivolumab 3 mg/kg IV Q2W plus Ipilimumab 1 mg/kg IV Q6W for 1 year). The primary endpoint of the study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life. This is an open label randomized controlled multi-center phase-2 superiority trial. Patients will be randomized in a 1:1 ratio to study arms. The trial will recruit 240 patients; recruitment commenced July 2019 and is anticipated to take 30 months. Detailed inclusion/exclusion criteria, toxicity management guidelines, and statistical plans for EORTC VESTIGE are described in the manuscript. Clinical Trial Registration: The trial is registered with www.ClinicalTrials.gov, identifier: NCT03443856.
dc.languageen
dc.publisherFrontiers Media S.A.
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectOncology
dc.subjectgastric cancer
dc.subjectgastroesophageal cancer
dc.subjectimmunotherapy
dc.subjectchemotherapy
dc.subjectadjuvant
dc.subjectnivolumab
dc.subjectipilimumab
dc.subjectperioperative
dc.titleVESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study
dc.typeArticle
dc.date.updated2020-02-13T06:05:21Z
prism.publicationNameFrontiers in Oncology
prism.volume9
dc.identifier.doi10.17863/CAM.49167
dcterms.dateAccepted2019-11-12
rioxxterms.versionofrecord10.3389/fonc.2019.01320
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.identifier.eissn2234-943X


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)